Medicare IVIG Access Enhancement Act of 2025
Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.
Medicare IVIG Access Enhancement Act of 2025
This bill provides for Medicare coverage of in-home administration of intravenous immune globulin to treat chronic inflammatory demyelinating polyneuropathy (CIDP) or multifocal motor neuropathy. (CIDP is an autoimmune condition that causes symptoms such as muscle weakness and numbness; multifocal motor neuropathy is a variant of CIDP that only causes asymmetric muscle weakness.)
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Introduced in House Formatted Text PDF Formatted XML
Cite this page
U.S. Congress. (2026). H.R. 1143: Medicare IVIG Access Enhancement Act of 2025. 119th Congress. Open America. https://openamerica.io/bill/119-HR-1143/
"H.R. 1143: Medicare IVIG Access Enhancement Act of 2025." 119th Congress, 2026, Open America, https://openamerica.io/bill/119-HR-1143/.
H.R. 1143, 119th Cong. (2026), https://openamerica.io/bill/119-HR-1143/.
[H.R. 1143: Medicare IVIG Access Enhancement Act of 2025](https://openamerica.io/bill/119-HR-1143/)